Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CARA | US
0.00
0.68%
Healthcare
Biotechnology
30/06/2024
17/10/2024
0.27
0.26
0.27
0.25
Cara Therapeutics Inc. a commercial-stage biopharmaceutical company focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate including Oral KORSUVA (difelikefalin) which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics Inc. has license agreements with Maruishi Pharmaceutical Co. Ltd to develop manufacture and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop manufacture and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford Connecticut.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
45.4%1 month
64.5%3 months
59.4%6 months
113.9%-
-
1.19
4.07
0.65
-2.32
4.83
-
-104.72M
15.07M
15.07M
-
-1.64K
-
-85.70
-184.32
2.11
1.76
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.03
Range1M
0.07
Range3M
0.15
Rel. volume
0.68
Price X volume
53.70K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.7 | 16.46M | 0.00% | n/a | 0.64% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.71 | 15.99M | 0.00% | n/a | 837.11% |
Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.55 | 15.81M | 8.39% | n/a | 2.12% |
Orgenesis Inc | ORGS | Biotechnology | 3.238 | 15.45M | -4.48% | n/a | -84.02% |
LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.2328 | 15.24M | -3.08% | n/a | 118.63% |
ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.539 | 15.10M | -3.94% | n/a | 49.00% |
IMNN | IMNN | Biotechnology | 0.9787 | 14.09M | -2.12% | n/a | 37.13% |
Aytu BioScience Inc | AYTU | Biotechnology | 2.29 | 14.08M | 0.11% | n/a | 54.59% |
Cingulate Inc. Common Stock | CING | Biotechnology | 4.49 | 13.67M | 2.05% | n/a | 10.72% |
NRXP | NRXP | Biotechnology | 1.265 | 13.60M | 2.85% | n/a | -46.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.32 | 0.53 | Cheaper |
Ent. to Revenue | 4.83 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.19 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 59.40 | 72.92 | Par |
Debt to Equity | 4.07 | -1.24 | Expensive |
Debt to Assets | 0.65 | 0.25 | Expensive |
Market Cap | 15.07M | 3.78B | Emerging |